20-047
P. Britz-McKibbin N. Pai
US and CA national phase
Proof of principle data available
Sunita Asrani Associate Director Business Development and Copyright
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is an idiopathic chronic gastrointestinal (GI) condition that affects pediatric populations with about 20- 30% of IBD patients experiencing their first symptoms before the age of 18. Current procedures dedicated to diagnosing the disease rely on invasive and expensive endoscopic imaging and tissue biopsies that can lead to indeterminate results. New insights into the distinctive pathophysiology of IBD are critical for early detection and optimal treatment strategies for individual patients.
McMaster researchers have developed a method to differentiate between UC and CD through a urinary sample. Researchers have determined distinct urine-based biomarkers and metabolic phenotypes of IBD patients thereby permitting differentiation between CD and UD. This allows for earlier diagnosis and the facilitation of treatment monitoring while also potentially avoiding the need for invasive colonoscopic imaging and tissue biopsies.
Medical Applications: